Formulation Development
EXECUTIVE INTERVIEW - Coya Therapeutics: Unlocking the Power of Tregs to Combat Inflammation & Fight Neurodegenerative Diseases
Dr. Howard Berman, Founder and CEO of Coya Therapeutics, discusses how the company is leveraging Tregs, its investigational products and the conditions targeted, Coya’s significant partnership with Dr. Reddy’s Laboratories, and his goals throughout the next 5 years.
Voyager Enters License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14
Voyager Therapeutics, Inc. recently announced Novartis AG has agreed to license a novel capsid generated from Voyager’s TRACER capsid discovery platform for use in a…
Shuttle Pharma Announces Issuance of US Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease
Shuttle Pharmaceuticals recently announced the issuance of US Patent No. 12,077,515, titled Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease. This patent was…
Rigel Announces First Patient Enrolled in Phase 1b/2 Trial of REZLIDHIA (olutasidenib) in mIDH1 AML
Rigel Pharmaceuticals, Inc.recently announced the first patient has been enrolled in a Phase 1b/2 triplet therapy trial of decitabine and venetoclax in combination with REZLIDHIA…
Sonoma Biotherapeutics Receives $45-Million Milestone Payment From Regeneron
Sonoma Biotherapeutics, Inc. recently announced it has received a $45-million milestone payment from Regeneron Pharmaceuticals, Inc., under the terms of its active collaboration to discover,…
Recipharm Introduces ReciPredict to Revolutionize Drug Product Development & Manufacturing
Recipharm recently announced the launch of ReciPredict, a cutting-edge platform for Quality by Design (QbD), designed to transform the landscape of drug product development, tech…
Kymanox & SHL Medical Enter Non-Exclusive Strategic Partnership Agreement to Support Delivery of Modern Medicines
Kymanox Corporation and SHL Medical AG recently announced they have signed a non-exclusive strategic partnership agreement. This collaboration establishes a reciprocal preferred partnership between the…
Invivyd Doses First Participants in Phase 1 Clinical Trial of Next Generation Monoclonal Antibody Candidate for COVID-19
Invivyd, Inc. recently announced dosing of the first participants in the Phase 1 healthy volunteer clinical trial of VYD2311, a next-generation monoclonal antibody (mAb) candidate…
Novartis Begins Construction of Two New Radioligand Therapy Facilities in the US
Novartis recently announced the construction of two new radioligand therapy (RLT) manufacturing facilities in the US that will extend its world-class manufacturing and supply chain…
Allyx Therapeutics Announces First Parkinson’s Disease Patient Treated
Allyx Therapeutics recently announced the first patient has been dosed with its lead compound, ALX-001, in a new clinical study assessing safety, pharmacokinetics and potential…
Pharma Two B & Hepion Pharmaceuticals Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger
Pharma Two B Ltd. and Hepion Pharmaceuticals, Inc. recently announced the filing of a registration statement of Pharma Two B on Form F-4 with the…
LIXTE Receives US Patent Issue Notification for Immune Oncology
LIXTE Biotechnology Holdings, Inc. recently announced it has received a Notice of Allowance from the United States Patent and Trademark Office for US Patent application…
Avanti Polar Lipids Becomes Avanti Research, a Croda Brand
Avanti Polar Lipids, a global leader in lipids, recently announced its renewed offering for researchers and its transformation to Avanti Research. This marks another exciting…
Valneva & Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate
Valneva SE and Pfizer Inc. recently announced positive immunogenicity and safety data from their VLA15-221 Phase 2 study following a second booster vaccination of their Lyme disease…
Caribou Biosciences Announces Fast Track Designations to CB-010 in Refractory SLE & to CB-012 in Relapsed or Refractory AML
Caribou Biosciences, Inc. recently announced the US FDA granted Fast Track designations to CB-010 for refractory systemic lupus erythematosus (SLE) and to CB-012 for relapsed…
Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy
Cartesian Therapeutics, Inc. recently announced the first patient has been dosed in its first-in-human Phase 1 trial of Descartes-15, the Company’s next-generation autologous anti-B cell…
Sapio Sciences Advances The World's First AI-Powered Lab Assistant
Sapio Sciences recently announced significant enhancements to Sapio ELaiN, the pioneering AI-powered lab assistant that helps scientists streamline processes and work more efficiently. Sapio ELaiN, now…
Longeveron Announces Positive Type C Meeting With FDA Regarding Pathway to BLA
Longeveron Inc. recently announced the positive Type C meeting with the US FDA supporting the advancement of Lomecel-B, a proprietary, scalable, allogeneic, investigational cellular therapy…
Denali Therapeutics Announces Successful Meeting With FDA
Denali Therapeutics Inc. recently announced the outcome of a recent successful meeting with the Center for Drug Evaluation and Research (CDER) division of the US…
Nuvectis Pharma Announces Orphan Drug Designation for the Treatment of ARID1a-Deficient Ovarian, Fallopian Tube & Primary Peritoneal Cancers
Nuvectis Pharma, Inc. recently announced that NXP800 was granted Orphan Drug Designation by the US FDA for the treatment of AT-rich interactive domain-containing protein 1a…
